



**GlobalData»**  
PharmaPoint

**CROHN'S DISEASE –  
GLOBAL DRUG FORECAST AND MARKET ANALYSIS  
TO 2022**

## Executive Summary

Crohn's Disease: Key Metrics in the Seven Major Pharmaceutical Markets	
<b>2012 Epidemiology</b>	
Diagnosed Prevalent Population – Global	1.3 million
Diagnosed Treated Population – Global	0.8 million
<b>2012 Market Sales</b>	
US	\$2,126.1m
5EU	\$396.9m
Japan	\$227.8m
<b>Total 7MM</b>	<b>\$2,750.8m</b>
<b>Total Global</b>	<b>\$3,168.8m</b>
<b>Pipeline Assessment</b>	
Number of drugs in Phase III	4
Number of first-in-class drugs in the late-stage pipeline	3
<b>Most Promising Pipeline Drugs</b>	
Entyvio (vedolizumab)	\$659.2m
Stelara (ustekinumab)	\$399.5m
<b>Key Events (2012–2022)</b>	
<b>Level of Impact</b>	
Entyvio launch in 2014 (US, EU)	↑↑↑
Remicade (infliximab) patent expiry in 2018 (US)	↓↓↓
Infliximab biosimilars launch in 2015 (EU)	↑↑
Stelara launch in 2015 (US, EU)	↑↑
Humira (adalimumab) patent expiry in 2016 (US)	↓↓↓
<b>2022 Market Sales</b>	
US	\$2,871.3m
5EU	\$457.5m
Japan	\$288.2m
<b>Total 7MM</b>	<b>\$3,617.0m</b>
<b>Total Global</b>	<b>\$4,194.8m</b>
Source: GlobalData	
Global = US, France, Germany, Italy, Spain, UK, Japan, Canada, China, and India; 7MM = US, France, Germany, Italy, Spain, UK, and Japan; 5EU = France, Germany, Italy, Spain, and UK	

Above mentioned table presents the key metrics for Crohn's disease (CD) in the seven major pharmaceutical markets analyzed in this report: the US, France, Germany, Italy, Spain, the UK, and Japan. Additional markets covered in this report include Canada, China, and India, for a total of 10 markets.

### Launch of Non-Anti-TNF Drugs in the Near Term Will Fuel CD Market Growth to 2022

In 2012, GlobalData estimated that the global CD market was valued at \$3.2 billion across the 10 healthcare markets covered in our forecast: the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of the forecast period in 2022, sales across these markets will have grown steadily to reach \$4.2 billion, representing a Compound Annual Growth Rate (CAGR) of 2.8% over the 10-year timeframe, which includes four new market entrants and the launch of biosimilars.

Major growth drivers in the CD market over the forecast period include:

- The anticipated launch of the first non-anti-tumor necrosis factor (TNF) biologics, such as Takeda's Entyvio and Johnson & Johnson's (J&J's) Stelara
- High unmet need within the anti-TNFreactory patient group, which presents untapped market opportunities


## Executive Summary

- The uptake of infliximab and adalimumab biosimilars to the detriment of their established branded biologics, Remicade and Humira, respectively
- Continued uptake of select biologic brands — namely, Remicade in the US, Japan, and Canada; and Humira in the US
- Increasing prevalent cases of CD
- Improved access to pharmacological therapies in China and India

Conversely, major barriers to the growth of the CD market include:

- The fact that CD has an established biologics market, which creates a challenging environment for new market entrants
- Intensifying competition within the moderate-to-severe patient segment, as a number of new products are targeting this group
- Brand erosion following the patent expiry of the market-leading therapies, Remicade and Humira
- The complex pathogenesis of CD, which creates an additional challenge in demonstrating clinical efficacy during clinical development

Below mentioned figure illustrates the global sales for CD by region during the 10-year forecast period.



## Executive Summary

### Research and Development and Corporate Strategies Will Be Focused on the Competitive Biologics Space


- In general, companies striving to enter the CD market appear most focused on patients who are refractory to the first-line anti-TNF biologics, Remicade and Humira. This population remains the most underserved group, with limited therapeutic options and high clinical unmet need. While GlobalData believes this strategy is a viable approach for late-stage CD products, competition within this patient segment is set to intensify from 2014 onwards, following the launch of Takeda's Entyvio and J&J's Stelara. Therefore, companies with early-phase products targeting this patient group may struggle to gain a foothold in the future CD market.
- Indication expansion across autoimmune diseases with biologic brands is another common strategy for companies operating in this therapeutic area. J&J is adept at applying this strategy and appears to be using its leading psoriasis brand, Stelara, an interleukin (IL)-12/23 inhibitor, to address the CD market, while Simponi (golimumab), its biologic brand that is currently approved for other diseases, including rheumatoid arthritis (RA), is targeting the other major type of inflammatory bowel disease (IBD), ulcerative colitis (UC).
- Over the 10-year forecast period, of all the current CD market players, J&J appears to be best positioned to remain a key contender. Although patent expiry looms for its leading brand, Remicade, in 2015 (EU) and 2018 (US), Stelara is forecast to launch in 2015 and will help J&J retain some of its current CD market share, albeit not at the same level as that gained with Remicade. A number of new market players will emerge in the early- to mid-term of the forecast period, and their pipeline drugs are expected to compete against Remicade and AbbVie's Humira. However, they will not be strong enough to displace J&J's current hold on the market. Still, J&J's stance will be weakened, particularly by Takeda, which will play a key role in seizing market share from the biologic brands with Entyvio.
- AbbVie's current leading stance in the CD space is solely attributable to Humira. However, Humira's patent expiries in 2016 (US) and 2018 (EU) will expose the brand to biosimilar competition. With one drug in AbbVie's 2014 CD pipeline, GLPG0634, which is being developed through its collaboration with Galapagos, the ability of Humira to retain sales through strong marketing strategies and tactical pricing in the face of rising biosimilar competition will govern the strength of AbbVie's position at the end of the forecast period. With sales beginning a downward

## Executive Summary

trajectory from 2016 on, Humira will lose almost half its 2012 market value by 2022, thereby dampening AbbVie's CD market status. For UCB and Biogen Idec, their market share and position in CD also will have declined dramatically by 2022, owing to the fact that they are not expected to gain any significant boost in patient share over the forecast period, while the uptake of new products will steer their respective brands, Cimzia (certolizumab pegol) and Tysabri (natalizumab), further down the CD treatment paradigm.

- Although another new market player, ChemoCentryx, will emerge in 2019, with its small-molecule pipeline candidate vercirnon, it will play a less prominent role in the CD market over the forecast period.

Below mentioned figure provides an analysis of the portfolio gap among the companies in the CD market during the forecast period.



### A Number of Clinical Unmet Needs Exist in the CD Treatment Realm

According to key opinion leaders (KOLs) interviewed by GlobalData, the level of unmet need in the CD marketplace is moderate, with clinical unmet needs being the main driver for research into this autoimmune disease. The most pressing clinical unmet need is for reliable disease diagnostic tools, such as biomarkers, as these could aid physicians in predicting the disease course, which would, in turn, allow them to effectively tailor their treatment approach.



## Executive Summary

Another significant clinical unmet need lies in the management of patients with moderate to severe CD. These patients eventually lose their response to anti-TNF therapy, which presents a challenge for gastroenterologists, as there are few remaining treatment options. As such, there remains a gap in the market for novel therapies to treat this patient group. Having the most clinically-advanced therapy in targeting this patient group, Takeda appears to be the company best positioned to address this unmet need, and could set a precedent with its novel, gut-selective biologic, Entyvio. The launch of Entyvio into the CD space is imminent, as on December 9, 2013, the Food and Drug Administration's (FDA's) Gastrointestinal Drugs Advisory Committee unanimously voted for its approval as a treatment for adults with moderately to severely active CD.

Focusing on environmental unmet needs, the most pertinent of these is increasing patient awareness of CD, particularly within emerging markets, such as India and China. Improving patient awareness may steer more patients in these markets to seek treatment. This, in turn, would present market expansion opportunities for CD drug developers.

### Emerging Therapies Leave Limited Opportunity Within the TNF-Refractory Population

Currently, anti-TNF agents are entrenched in the treatment of CD, but the use of these drugs is associated with the development of immunogenicity. This means that some patients develop infusion site reactions, continue to have active disease, or relapse in spite of biologic therapy. Takeda and J&J are aiming to address the issue of immunogenicity while providing a therapeutic option for anti-TNF refractory patients with their respective biologics, Entyvio and Stelara. With both candidates targeting the anti-TNF refractory patient group and set to enter the CD marketplace by 2015, the need for additional therapies for this population is expected to be met during the coming decade.

The pathophysiology of CD is complex, with a diverse array of possible triggers. This presents several therapeutic targets for drug therapies in CD. Targeting other pathways involved in the cascade that leads to CD, such as the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, may provide physicians with a greater armamentarium of CD treatments. This presents the opportunity for drug developers to tap into niche segments of the CD population, provide targeted therapy, and circumvent the need for surgery.

## Executive Summary

### Novel Biologics and Biosimilars Will Reshape the CD Competitive Landscape

Although GlobalData forecasts four new product launches (Entyvio, Stelara, vercirnon, and Prochymal [remestemcel-L]) during the 2012–2022 forecast period, growth within the 10 CD healthcare markets covered in this report will largely be driven by the strong uptake of two of the new products: Takeda's Entyvio and J&J's Stelara. The launch of these pipeline candidates in 2014 and 2015, respectively, in the US, EU, and Canadian markets will boost year-on-year growth from 2014 to 2022 across these major markets, as they will contribute up to \$1.0 billion in global CD sales in 2022. This anticipated revenue represents 25% of the overall 2022 global CD market value.


There is palpable excitement among physicians and patients for Entyvio to reach the CD market, owing to the biologic's novel mechanism of action (MOA) as a gut-selective  $\alpha 4\beta 7$  integrin inhibitor, its promising Phase III efficacy and safety profile, and its potential to meet the high unmet need for a therapeutic option for patients who are refractory to the established TNF inhibitors, Remicade and Humira. Taking into account the opinions of leading gastroenterologists, the proposed label in Takeda's regulatory documentation for Entyvio, and the clinical trial design of Stelara's Phase III program, both drugs are likely to be positioned as second-line biologic agents. This means their primary target population will be anti-TNF failures, placing them in direct

competition with Remicade, Humira, Cimzia, and Tysabri.

In addition to the brand dynamics noted above, the launch of biosimilars will contribute to the upward trajectory of the global CD market. Unlike generics of small molecules, which are often priced at a substantial discount to the originator brand, biosimilars of the mAb therapies for CD, Remicade and Humira, are expected to be priced only marginally lower than the biologic brand (at an approximately 20% discount). Although the European Medicines Agency (EMA) has an established pathway for biosimilar approval, which led to the approval of Hospira/Celltrion's Inflectra (infliximab), a biosimilar version of Remicade, in September 2013, the FDA is currently refining its regulatory pathway in this regard. GlobalData assumes that the latter agency will implement guidelines for the approval of biosimilars by the time of Remicade's patent expiry in 2018.

## Executive Summary

Below mentioned figure provides a competitive assessment of the late-stage pipeline agents in CD during the forecast period.



### What Do Physicians Think?

Following the approval of Hospira/Celltrion's Inflectra, a biosimilar of the market-leading biologic, Remicade, in September 2013 for the multiple autoimmune indications for which Remicade is approved, some KOLs highlighted that they would await data from a CD- or an IBD-specific trial before prescribing Inflectra for their CD or UC patients. This, in turn, could limit the initial uptake of Inflectra.

*"I am not interested in [using] Inflectra in [my] IBD [patients] unless it is tested in IBD[-specific] clinical trials."*

*[EU] key opinion leader*

KOLs stressed that predicting the course of CD remains the most challenging aspect of managing their CD patients.

*"I think the most challenging aspect is to, first of all, risk-stratify as to what patients are going to do badly in the long run, and trying to tailor an effective therapy for them."*

*[Outside-US] key opinion leader*



## Executive Summary

Having biomarkers included in their diagnostic tools is important to gastroenterologists, as it could allow them to effectively predict the course of CD in a given patient and allow them to offer a personalized treatment approach.

*"I think we need a more biomarker-based approach....I think we are falsely diagnosing early disease. With Crohn's, two days of endoscopic techniques and two days of radiological assessments are precise enough to allow you to see the morphological damage, but in pre-stage patients at risk of developing the disease, we do have difficulties in properly assessing the disease."*

[EU] key opinion leader

KOLs stressed their desire for new drug therapies to treat the anti-TNF refractory patient segment.

*"We are learning that the anti-TNF therapies have a limited lifespan....We are going to run into a problem where we have a lot of people losing response to anti-TNF therapy early on in their disease course, and then they don't have an option later on."*

[US] key opinion leader

*"All these drugs [anti-TNFs] have a finite natural history, as we rapidly move from one drug to another, and five years down the road, someone with a history of Crohn's is going to be with no treatment options."*

[US] key opinion leader

KOLs validated that emerging therapies with novel MOAs will form the basis of their treatment paradigm.

*"In the future, what we will do is either switching of anti-TNF therapies, or we will switch to alternative mechanisms, and we will soon have [the] alpha4beta7, vedolizumab."*

[EU] key opinion leader

According to KOLs, anti-IL-6 therapies, which are currently in early clinical development, hold promise.

*"There are so many companies out there with anti-IL-6 agents that I feel there could be a new paradigm coming up, which could add to the value of innovation...not just to the molecule, but also to the way we use it."*

[EU] key opinion leader

## Table of Contents

**1 Table of Contents**

<b>1</b>	<b>Table of Contents .....</b>	<b>10</b>
1.1	List of Tables .....	19
1.2	List of Figures .....	23
<b>2</b>	<b>Introduction .....</b>	<b>25</b>
2.1	Catalyst.....	25
2.2	Related Reports .....	26
2.3	Upcoming Related Reports .....	26
<b>3</b>	<b>Disease Overview .....</b>	<b>27</b>
3.1	Etiology and Pathophysiology .....	27
3.1.1	Etiology .....	27
3.1.2	Pathophysiology.....	27
3.2	Symptoms.....	31
3.3	Prognosis.....	32
3.4	Quality of Life.....	33
<b>4</b>	<b>Epidemiology .....</b>	<b>34</b>
4.1	Risk Factors and Comorbidities .....	34
4.1.1	Up to 60% of CD patients experience reduced bone density .....	35
4.1.2	One third of patients with CD suffer from psychiatric illness .....	35
4.1.3	Arthritis affects 25% of CD Patients.....	35
4.1.4	Gastrointestinal complications often occur as part of CD.....	36
4.2	Global Trends .....	36

## Table of Contents

4.2.1	US.....	37
4.2.2	5EU.....	38
4.2.3	Japan.....	39
4.2.4	Canada.....	40
4.2.5	China.....	40
4.2.6	India.....	41
4.3	Forecast Methodology.....	41
4.4	Sources Used.....	44
4.4.1	US.....	44
4.4.2	France.....	44
4.4.3	Germany.....	45
4.4.4	Italy.....	45
4.4.5	Spain.....	46
4.4.6	UK.....	47
4.4.7	Japan.....	47
4.4.8	Canada.....	48
4.4.9	China.....	48
4.4.10	India.....	49
4.5	Forecast Assumptions and Methods.....	49
4.5.1	Incident Cases.....	49
4.5.2	Prevalent Cases.....	52
4.5.3	Sources Not Used.....	55
4.6	Epidemiological Forecast for CD.....	56

## Table of Contents

4.6.1	Incident Cases of CD .....	56
4.6.2	Prevalent Cases of CD.....	61
4.7	Discussion .....	68
4.8	Limitations of the Analysis.....	70
4.9	Strengths of the Analysis .....	70
<b>5</b>	<b>Disease Management.....</b>	<b>71</b>
5.1	Treatment Overview.....	72
5.2	US.....	77
5.2.1	Diagnosis .....	77
5.2.2	Clinical Practice.....	77
5.3	France .....	79
5.3.1	Diagnosis .....	79
5.3.2	Clinical Practice.....	80
5.4	Germany.....	81
5.4.1	Diagnosis .....	81
5.4.2	Clinical Practice.....	81
5.5	Italy .....	83
5.5.1	Diagnosis .....	83
5.5.2	Clinical Practice.....	83
5.6	Spain .....	85
5.6.1	Diagnosis .....	85
5.6.2	Clinical Practice.....	85
5.7	UK.....	87

## Table of Contents

5.7.1	Diagnosis .....	87
5.7.2	Clinical Practice.....	87
5.8	Japan.....	89
5.8.1	Diagnosis .....	89
5.8.2	Clinical Practice.....	89
5.9	Canada.....	91
5.9.1	Diagnosis .....	91
5.9.2	Clinical Practice.....	91
5.10	China .....	92
5.10.1	Diagnosis .....	92
5.10.2	Clinical Practice.....	92
5.11	India.....	93
5.11.1	Diagnosis .....	93
5.11.2	Clinical Practice.....	94
6	<b>Competitive Assessment .....</b>	<b>95</b>
6.1	Overview.....	95
6.2	Strategic Competitor Assessment .....	96
6.3	Product Profiles – Major Brands.....	98
6.3.1	Remicade (infliximab).....	98
6.3.2	Humira (adalimumab).....	104
6.3.3	Cimzia (certolizumab pegol).....	111
6.3.4	Tysabri (natalizumab).....	116
6.3.5	Other Marketed Products .....	122



## Table of Contents

6.4	Biosimilars .....	123
6.4.1	Introduction .....	123
6.4.2	Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases .....	124
6.4.3	Biosimilars in the Immunology Community .....	125
6.4.4	By the Numbers: Biosimilars in Development.....	125
6.4.5	The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry .....	128
6.4.6	Biosimilars' Forecast .....	129
7	Opportunity and Unmet Need .....	131
7.1	Overview.....	131
7.2	Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach .....	132
7.3	More Therapies for Anti-TNF-Refractory Patients .....	133
7.4	Unmet Needs Gap Analysis .....	134
7.5	Targeted Therapies.....	135
7.6	Predictive Tools for Early Diagnosis and Treatment.....	136
8	Pipeline Assessment.....	137
8.1	Overview.....	137
8.2	Clinical Trial Mapping.....	138
8.2.1	Clinical Trials by Country.....	138
8.3	Clinical Trials by Phase and Trial Status .....	139
8.4	Promising Drugs in Clinical Development.....	140
8.4.1	Entyvio (vedolizumab) .....	142
8.4.2	Stelara (ustekinumab) .....	154
8.4.3	Vercirnon (formerly GSK1605786) .....	162

## Table of Contents

8.4.4	Prochymal (Remestemcel-L) .....	171
8.5	Other Late-Stage Pipeline Products .....	177
8.5.1	Cx601.....	177
8.5.2	RHB-104 (clarithromycin + clofazimine + rifabutin) .....	180
9	Current and Future Players.....	184
9.1	Overview.....	184
9.2	Trends in Corporate Strategy .....	186
9.3	Company Profiles.....	189
9.3.1	Johnson & Johnson.....	189
9.3.2	AbbVie .....	191
9.3.3	UCB .....	193
9.3.4	Biogen Idec.....	194
9.3.5	Takeda.....	196
9.3.6	ChemoCentryx .....	198
10	Market Outlook .....	200
10.1	Global Markets.....	200
10.1.1	Forecast.....	200
10.1.2	Drivers and Barriers – Global Issues .....	204
10.2	US.....	209
10.2.1	Forecast.....	209
10.2.2	Key Events.....	212
10.2.3	Drivers and Barriers .....	212
10.3	France .....	216

## Table of Contents

10.3.1	Forecast .....	216
10.3.2	Key Events .....	220
10.3.3	Drivers and Barriers .....	220
10.4	Germany .....	223
10.4.1	Forecast .....	223
10.4.2	Key Events .....	227
10.4.3	Drivers and Barriers .....	227
10.5	Italy .....	230
10.5.1	Forecast .....	230
10.5.2	Key Events .....	234
10.5.3	Drivers and Barriers .....	234
10.6	Spain .....	237
10.6.1	Forecast .....	237
10.6.2	Key Events .....	241
10.6.3	Drivers and Barriers .....	241
10.7	UK .....	244
10.7.1	Forecast .....	244
10.7.2	Key Events .....	248
10.7.3	Drivers and Barriers .....	248
10.8	Japan .....	251
10.8.1	Forecast .....	251
10.8.2	Key Events .....	255
10.8.3	Drivers and Barriers .....	255

## Table of Contents

10.9	Canada .....	259
10.9.1	Forecast .....	259
10.9.2	Key Events .....	263
10.9.3	Drivers and Barriers .....	263
10.10	China .....	265
10.10.1	Forecast .....	265
10.10.2	Key Events .....	268
10.10.3	Drivers and Barriers .....	268
10.11	India .....	270
10.11.1	Forecast .....	270
10.11.2	Key Events .....	273
10.11.3	Drivers and Barriers .....	273
11	Appendix .....	276
11.1	Bibliography .....	276
11.2	Abbreviations .....	289
11.3	Methodology .....	293
11.4	Forecasting Methodology .....	293
11.4.1	Diagnosed CD Patients .....	293
11.4.2	Percent Drug-Treated Patients .....	294
11.4.3	Drugs Included in Each Therapeutic Class .....	294
11.4.4	Launch and Patent Expiry Dates .....	294
11.4.5	General Pricing Assumptions .....	295
11.4.6	Individual Drug Assumptions .....	296

## Table of Contents

11.4.7	Generic Erosion .....	299
11.4.8	Pricing of Pipeline agents.....	300
11.5	Physicians and Specialists Included in This Study .....	301
11.6	Primary Research – Prescriber Survey .....	303
11.7	About the Authors .....	304
11.7.1	Author/Reviewer.....	304
11.7.2	Epidemiologist.....	304
11.7.3	Global Head of Healthcare .....	305
11.8	About GlobalData.....	306
11.9	Disclaimer .....	306



## Table of Contents

## 1.1 List of Tables

Table 1:	Symptoms of CD .....	32
Table 2:	Comorbidities for CD .....	34
Table 3:	Sources of Incidence Data Used in This Analysis .....	42
Table 4:	Sources of Prevalence Data Used in This Analysis.....	43
Table 5:	All Markets, Incident Cases of CD, Ages ≥10 Years, Men and Women, N, 2012–2022.....	56
Table 6:	All Markets, Incident Cases of CD, by Age, Men and Women, N (Row Total), 2012 .....	58
Table 7:	All Markets, Incident Cases of CD, by Sex, Ages ≥10 Years, N (%), 2012.....	59
Table 8:	All Markets, Prevalent Cases of CD, Ages ≥10 Years, Men and Women, N, 2012–2022 .....	62
Table 9:	All Markets, Prevalent Cases of CD, by Age, Men and Women, N, 2012.....	64
Table 10:	All Markets, Prevalent Cases of CD, by Sex, Ages ≥10 Years, N (%), 2012 .....	66
Table 11:	Treatment Guidelines for CD .....	73
Table 12:	Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 .....	75
Table 13:	Leading Branded Drugs Used to Treat CD.....	97
Table 14:	Product Profile – Remicade .....	99
Table 15:	Remicade SWOT Analysis, 2013.....	102
Table 16:	Global Sales Forecasts (\$) for Remicade, 2012–2022 .....	104
Table 17:	Product Profile – Humira .....	106
Table 18:	Humira SWOT Analysis, 2013 .....	109
Table 19:	Global Sales Forecasts (\$) for Humira, 2012–2022.....	111
Table 20:	Product Profile – Cimzia .....	112
Table 21:	Cimzia SWOT Analysis, 2013.....	114
Table 22:	Global Sales Forecasts (\$) for Cimzia, 2012–2022 .....	116
Table 23:	Product Profile – Tysabri .....	117

## Table of Contents

Table 24: Tysabri SWOT Analysis, 2013 .....	120
Table 25: Global Sales Forecasts (\$) for Tysabri, 2012–2022 .....	122
Table 26: Summary of the Minor Therapeutic Classes in CD, 2013 .....	123
Table 27: Biosimilars Pipeline, 2013 .....	126
Table 28: Global Sales Forecasts (\$) for Infliximab Biosimilars, 2012–2022 .....	129
Table 29: Global Sales Forecasts (\$) for Adalimumab Biosimilars, 2012–2022 .....	129
Table 30: Global Sales Forecasts (\$) for Certolizumab pegol Biosimilars, 2012–2022 .....	130
Table 31: Overall Unmet Needs in CD – Current Level of Attainment .....	132
Table 32: Clinical Unmet Needs in CD – Gap Analysis, 2013 .....	135
Table 33: CD – Clinical Trials by Phase and Status, 2013 .....	139
Table 34: Promising Drugs in Clinical Development for CD – Pipeline Phase, 2013 .....	140
Table 35: Comparison of Therapeutic Classes in Development for CD, 2013 .....	141
Table 36: Product Profile – Entyvio .....	143
Table 37: Efficacy of Entyvio in GEMINI II Studies of CD .....	144
Table 38: Entyvio SWOT Analysis, 2013 .....	152
Table 39: Global Sales Forecasts (\$) for Entyvio, 2012–2022 .....	154
Table 40: Product Profile – Stelara .....	155
Table 41: Comparison of Stelara's Phase IIb CERTIFI trial Efficacy Data Versus Tysabri's Phase III Efficacy Data in Anti-TNF Refractory CD Patients .....	157
Table 42: Stelara SWOT Analysis, 2013 .....	160
Table 43: Global Sales Forecasts (\$) for Stelara, 2012–2022 .....	162
Table 44: Product Profile – Vercirnon .....	164
Table 45: Vercirnon SWOT Analysis, 2013 .....	169
Table 46: Global Sales Forecasts (\$) for Vercirnon, 2012–2022 .....	170
Table 47: Product Profile – Prochymal .....	172

## Table of Contents

Table 48: Prochymal SWOT Analysis, 2013.....	175
Table 49: Global Sales Forecasts (\$) for Prochymal, 2012–2022.....	177
Table 50: Product Profile – Cx601.....	178
Table 51: Cx601 SWOT Analysis, 2013.....	179
Table 52: Product Profile – RHB-104.....	181
Table 53: RHB-104 SWOT Analysis, 2013.....	183
Table 54: Key Companies in the CD Market, 2013.....	185
Table 55: J&J's CD Portfolio Assessment, 2013.....	190
Table 56: J&J's CD SWOT Analysis, 2013.....	190
Table 57: AbbVie's CD Portfolio Assessment, 2013.....	192
Table 58: Abbott/AbbVie's CD SWOT Analysis, 2013.....	192
Table 59: UCB's CD Portfolio Assessment, 2013.....	193
Table 60: UCB's CD SWOT Analysis, 2013.....	194
Table 61: Biogen Idec's CD Portfolio Assessment, 2013.....	195
Table 62: Biogen Idec's CD SWOT Analysis, 2013.....	196
Table 63: Takeda's CD Portfolio Assessment, 2013.....	197
Table 64: Takeda's CD SWOT Analysis, 2013.....	197
Table 65: ChemoCentryx's CD Portfolio Assessment, 2013.....	198
Table 66: ChemoCentryx's CD SWOT Analysis, 2013.....	199
Table 67: Global Sales Forecasts (\$) for CD, 2012–2022.....	202
Table 68: Global CD Market – Drivers and Barriers, 2012–2022.....	204
Table 69: Sales Forecasts (\$) for CD in the United States, 2012–2022.....	210
Table 70: Key Events Impacting Sales for CD in the US, 2012–2022.....	212
Table 71: CD Market in the US – Drivers and Barriers, 2012–2022.....	212

## Table of Contents

Table 72: Sales Forecasts (\$) for CD in France, 2012–2022 .....	218
Table 73: Key Events Impacting Sales for CD in France, 2012–2022 .....	220
Table 74: CD Market in France – Drivers and Barriers, 2012–2022 .....	220
Table 75: Sales Forecasts (\$) for CD in Germany, 2012–2022 .....	225
Table 76: Key Events Impacting Sales for CD in Germany, 2012–2022 .....	227
Table 77: CD Market in Germany – Drivers and Barriers, 2012–2022 .....	227
Table 78: Sales Forecasts (\$) for CD in Italy, 2012–2022 .....	232
Table 79: Key Events Impacting Sales for CD in Italy, 2012–2022 .....	234
Table 80: CD Market in Italy – Drivers and Barriers, 2012–2022 .....	234
Table 81: Sales Forecasts (\$) for CD in Spain, 2012–2022 .....	239
Table 82: Key Events Impacting Sales for CD in Spain, 2012–2022 .....	241
Table 83: CD Market in Spain – Drivers and Barriers, 2012–2022 .....	241
Table 84: Sales Forecasts (\$) for CD in the UK, 2012–2022 .....	246
Table 85: Key Events Impacting Sales for CD in the UK, 2012–2022 .....	248
Table 86: CD Market in the UK – Drivers and Barriers, 2012–2022 .....	248
Table 87: Sales Forecasts (\$) for CD in Japan, 2012–2022 .....	253
Table 88: Key Events Impacting Sales for CD in Japan, 2012–2022 .....	255
Table 89: CD Market in Japan – Drivers and Barriers, 2012–2022 .....	255
Table 90: Sales Forecasts (\$) for CD in Canada, 2012–2022 .....	261
Table 91: Key Events Impacting Sales for CD in Canada, 2012–2022 .....	263
Table 92: CD Market in Canada – Drivers and Barriers, 2012–2022 .....	263
Table 93: Sales Forecasts (\$) for CD in China, 2012–2022 .....	266
Table 94: Key Events Impacting Sales for CD in China, 2012–2022 .....	268
Table 95: CD Market in China – Drivers and Barriers, 2012–2022 .....	268

## Table of Contents

Table 96: Sales Forecasts (\$) for CD in India, 2012–2022.....	271
Table 97: Key Events Impacting Sales for CD in India, 2012–2022.....	273
Table 98: CD Market in India – Drivers and Barriers, 2012–2022.....	273
Table 99: Key Launch Dates.....	294
Table 100: Key Patent Expiries.....	295
Table 101: Physicians Surveyed, By Country.....	303

## 1.2 List of Figures

Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) .....	28
Figure 2: Potential Biologic Drug Targets for CD .....	31
Figure 3: All Markets, Incident Cases of CD, Ages ≥10 Years, Men and Women, N, 2012–2022.....	57
Figure 4: All Markets, Incident Cases of CD, by Age, Men and Women, N, 2012 .....	58
Figure 5: All Markets, Incident Cases of CD, by Sex, Ages ≥10 Years, N, 2012 .....	60
Figure 6: All Markets, Age-Standardized Incidence Rate of CD, Ages ≥10 Years, Men and Women, 2012..	61
Figure 7: All Markets, Prevalent Cases of CD, Ages ≥10 Years, Men and Women, N, 2012–2022 .....	63
Figure 8: All Markets, Prevalent Cases of CD, by Age, Men and Women, N, 2012.....	65
Figure 9: All Markets, Prevalent Cases of CD, by Sex, Ages ≥10 Years, N, 2012.....	67
Figure 10: All Markets, Age-Standardized Prevalence of CD, Ages ≥10 Years, Men and Women, 2012.....	68
Figure 11: Patient Care Path for CD.....	74
Figure 12: CD Therapeutics – Clinical Trials by Country, 2013 .....	138
Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012–2022 .....	141
Figure 14: Company Portfolio Gap Analysis in CD, 2012–2022 .....	188
Figure 15: Global Sales for CD by Region, 2012–2022.....	203
Figure 16: Sales for CD in the US by Drug Class, 2012–2022 .....	211



## Table of Contents

Figure 17: Sales for CD in France by Drug Class, 2012–2022 .....	219
Figure 18: Sales for CD in Germany by Drug Class, 2012–2022.....	226
Figure 19: Sales for CD in Italy by Drug Class, 2012–2022.....	233
Figure 20: Sales for CD in Spain by Drug Class, 2012–2022 .....	240
Figure 21: Sales for CD in the UK by Drug Class, 2012–2022 .....	247
Figure 22: Sales for CD in Japan by Drug Class, 2012–2022 .....	254
Figure 23: Sales for CD in Canada by Drug Class, 2012–2022.....	262
Figure 24: Sales for CD in China by Drug Class, 2012–2022 .....	267
Figure 25: Sales for CD in India by Drug Class, 2012–2022 .....	272

## Introduction

## 2 Introduction

### 2.1 Catalyst

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such as:

- Takeda's alpha4beta7 inhibitor, Entyvio (vedolizumab)
- Johnson & Johnson's (J&J's) interleukin (IL)-12/23 inhibitor, Stelara (ustekinumab)

These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).

The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Patent expiries begin in 2015 for the current market leaders:

- J&J's Remicade
- AbbVie's Humira

Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Exciting times lay ahead for the CD marketplace, as the market events noted above are due to occur against the backdrop of a steadily rising global CD prevalent population. With the clinical unmet need for better diagnostic tools and treatment options for the anti-TNF-refractory population, CD represents an attractive autoimmune disease for drug developers. This, in turn should fuel commercial interest in this subtype of IBD.

## Introduction

### 2.2 Related Reports

- GlobalData (2013). PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2022, May 2013, GDHC48PIDR
- GlobalData (2013). PharmaPoint: Rheumatoid Arthritis – Global Drug Forecast and Market Analysis Event-Driven Update, July 2013, GDHC60PIDR

### 2.3 Upcoming Related Reports

- GlobalData (2014). PharmaPoint: Ulcerative Colitis – Global Drug Forecast and Market Analysis to 2022

## Appendix

### 11.8 About GlobalData

GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports and forecasts. Our analysis is supported by a 24/7 client support and analyst team.

GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan, Singapore, and Australia.

### 11.9 Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData.